These data implied that targeting Wee1 affects both CML cell proliferation and cell cycle regulation, thus revealing anticancer manifestations and potential clinical applications, which is presumably due to its involvement in the DNA damage response mechanism according to our hypothesis. Here, WEE1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.